Oligodendroglioma

Current Treatment Options in Neurology

Volumn 7, Issue 4, 2005, Pages 305-314

  Mason, Warren P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; CORTICOSTEROID; DACARBAZINE; DISULFIRAM; ETOPOSIDE; IRINOTECAN; LOMUSTINE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PLATINUM DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VINCRISTINE;

ANAPLASTIC CARCINOMA; AUTONOMIC NEUROPATHY; BEHAVIOR MODIFICATION; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER INCIDENCE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CRANIAL NEUROPATHY; CRANIOTOMY; CYTOREDUCTIVE SURGERY; DIET THERAPY; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; FATIGUE; GENETIC IDENTIFICATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KINESIOTHERAPY; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; MOLECULAR GENETICS; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; PAIN; PATHOLOGIST; PHYSIOTHERAPY; PREDICTION; PROGNOSIS; RADIATION DOSE; RELIABILITY; RESTLESSNESS; REVIEW; SEIZURE; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; SPEECH THERAPY; STEREOTAXIC SURGERY; THROMBOCYTOPENIA; TUMOR CLASSIFICATION;

EID: 22544453871     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0040-0     Document Type: Review

References (36)

1. Olson JD, Riedel E, DeAngelis LM: Long-term outcome of low-grade oligodendroglioma and mixed gliomas. Neurology 2000, 54:1442-1448.
2. Lebrun C, Fontaine D, Ramaioli A, et al.: Long-term outcome of oligodendrogliomas. Neurology 2004, 62:1783-1787.
3. Burger PC: What is an oligodendroglioma? Brain pathology 2002, 12:257-259.
4. Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479.
5. van den Bent MJ, Looijenga LHJ, Langenberg K, et al.: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003, 97:1276-1284.
6. Fallon KB, Palmer CA, Roth KA, et al.: Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004, 63:314-322.
7. Cairncross G, MacDonald D, Ludwin S, et al. for the National Cancer Institute of Clinical Trials Group. Chemotherapy for anaplastic oligodendrogliomas. J Clin Oncol 1994, 12:2013-2021.
8. Brandes AA, Tosoni A, Vastola F, et al.: Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. Cancer 2004, 101:2079-2085.
9. Paleologos NA, MacDonald DR, Vick NA, et al.: Neoadjuvant procarbazine, CCNU, and Vincristine for anaplastic and aggressive oligodendroglioma. Neurology 1999, 53:1141-1143.
10. van den Bent MJ, Taphoorn MJB, Brandes AA, et al.: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003, 21:2525-2528.
11. van den Bent MJ, Chinot O, Boogerd W, et al.: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003, 14:599-602.
12. Chinot O-L, Honore S, Dufour H, et al.: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001, 19:2449-2455.
13. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7:839-845.
14. Hoang-Xuan K, Capelle L, Kujas M, et al.: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004, 22:3133-3138.
15. Buatti J, Meeks S, Ryken T, Carlisle T: Low-grade gliomas: answering one question in a myriad of new questions. J Clin Oncol 2002, 20:2223-2224.
16. Taphoorn M, Schiphorst A, Snoek F, et al.: Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994, 36:48-54.
17. Brada M, Viviers L, Abson C, et al.: Phase II study of primary temozolomide chemotherapy in patients with VMO grade II gliomas. Ann Oncol 2003, 24:1715-1721.
18. Quinn J, Reardon DA, Friedman AH, et al.: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003, 21:646-651.
19. Buckner JC, Gesme Jr D, O'Fallon JR, et al.: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003, 21:251-255.
20. Cairncross G, Seiferheld W, Shaw E, et al.: An intergroup randomized controlled clinical trial (RTC) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma: initial report of RTOG 94-02. Neuro-oncol 2004, 6:371.
21. Stupp R, Mason W, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 2005, In press.
22. Petersen K, Paleologos N, Forsyth P, et al.: Salvage chemotherapy for oligodendroglioma. J Neurosurg 1996, 85:597-601.
23. Chamberlain MC, Kormanik PA: Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J Clin Oncol 1997, 15:3427-3432.
24. Soffietti R, Nobile M, Ruda R, et al.: Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (Procarbazine, lomustine, and Vincristine) chemotherapy. A phase II study. Cancer 2004, 100:807-813.
25. Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neuro-oncol 2002, 59:157-163.
26. Brandes AA, Basso U, Vastola F, et al.: Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol 2003, 14:1727-1731.
27. Shaw E, Arusell R, Scheithauer B, et al.: Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Group/Radiation therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002, 20:2267-2276.
28. Karim A, Matt B, Hatlevoli R, et al.: A randomized trial no dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiation Oncology Biol Phys 1996, 36:549-556.
29. Karim A, Afra D, Cornu P, et al.: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BR04: an interim analysis. Int J Radiation Oncology Biol Phys 2002, 52:316-324.
30. Bauman GS, Ino Y, Ueki K, et al.: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiation Oncology Biol Phys 2000, 48:825-830.
31. Puduvalli VK, Hashmi M, McAllister LD, et al.: Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 2003, 65:259-266.
32. Laws ER, Shaffrey ME, Morris A, Anderson Jr FA: Surgical management of intracranial gliomas-does radical resection improve outcome? Acta Neurochir 2002, 85(Suppl):47-53.
33. Pignatti F, van den Bent M, Curran D, et al.: Prognsotic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002, 20:2076-2084.
34. Abrey LE, Childs BH, Paleologos N, et al.: High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neuro-oncol 2003, 65:127-134.
35. Raghavan R, Balani J, Perry A, et al.: Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 2003, 62:530-537.
36. Fisher BJ, Bauman GS, Leighton CE, et al.: Low-grade gliomas in children: tumor volume response to radiation. J Neurosurg 1988, 88:969-974.